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PROGRESS REPORT 
The goals of our research program are: (1) to answer key questions 
regarding the biochemical mechanisms responsible for the antihypertensive activity 
we have demonstrated for certain compounds of our design; (2) to bioassay the 
potential antihypertensive activity of other compounds we have already designed and 
synthesized based on the ideas of this proposal; and (3) to extend our efforts by 
continuing to design and evaluate other classes of compounds potentially capable of 
exhibiting antihypertensive activity through the modification of adrenergic 
neuronal activity. 
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Substantial progress has been made in all of these areas. The following 
paragraphs summarize our progress during this second year of the current project 
period. 
Experiments in Chromaffin Vesicle Ghosts. As anticipated, over the 
course of this past year we have greatly expanded this aspect of our research 
program. In our view, such experiments will serve to forge the critical link 
between the enzymology of our novel neurotransmitter analogs and the potent 
biological activity we are observing in our animal studies. A specific focus at 
this time are our selenium-containg compounds, with corresponding experiments being 
carried out with the sulfide cognates. The working hypothesis we are testing is as 
follows. We visualize that the biological effects we observe with our selenides, 
sulfides, olefins, etc. (e.g., antihypertensive activity in SHR) are initiated 
through a mechanism involving initial uptake into neuronal cells, followed by 
uptake into neurotransmitter storage vesicles. After uptake, we wish to 
demonstrate that by virtue of their ability to act either as DBM substrates or 
inhibitors, our compounds effectively reduce the amount of norepinephrine (NE) 
available for release and post-synaptic activation of adrenergic receptors. We 
expect that specific biochemical processes will be operative for each of the 
several classes of compounds we are developing. For example, in the specific case 
of the selenides, we anticipate that DBM-mediated turnover of the selenides results 
in ascorbate depletion within vesicles, the striking discovery we have confirmed in 
our in-vitro enzymological work, and now wish to confirm this in vesicle ghosts. 
We have now conclusively demonstrated that our selenides and sulfides are 
indeed actively taken up across the vesicle membrane in a process which is strictly 
dependent on Mg-ATP. Importantly, we have developed the technology to 
simultaneously determine catecholamines and ascorbate levels using 
HPLC/electrochemical detection, and to separately determine the concentration of 
each of these species inside or outside of the vesicles. In a manuscript under 
submission to J. Biol. Chem, we demonstrate conclusively that the DBM in our 
vesicles is mainly (80%) the membrane-bound species; that our vesicles are fully 
functional in taking up DA and converting it to NE; that uptake is strictly Mg-ATP 
dependent; and that conversion is requires DBM turnover and electron consumption 
from ascorbate. Furthermore, we demonstrate that external ascorbate can support 
DBM turnover within the vesicles, with electrons flowing across the membrane 
serving to recycle internal ascorbate. A stoichiometric relationship exists 
between external electrons available and total NE production. Importantly, our 
data clearly indicate that it is the internal ascorbate which functions as the 
immediate reductant for facile DEM turnover; a much slower endogenous rate of NE 
production does occur in the absence of ascorbate, and this is attributable to slow 
catecholamine-supported DBM turnover. 
It is clear from these reults that membrane-bound DBM within chromaffin 
vesicles indeed utilizes directly internal ascorbate as the immediate reductant 
supporting catalytic turnover. This is a critical point if our selenides are to 
deplete ascorbate in adrenergic neurons, where the DBM is membrane-bound and not 
the soluble enzyme universally isolated by biochemists from adrenal medulla. In 
the past two months, we have established that the selenides are actively 
transported across the vesicle membrane and that they do, indeed, cause a depletion 
of reduced ascorbate within the vesicles concommitant with DEM turnover. 
Depletions of about 80% have been observed in our experiments, and we are now 
carrying out comparison studies with our sulfide substrates. Furthermore, we have 
also shown that the sulfides are indeed converted to sulfoxides by DBM turnover 
within the vesicles, an important prerequisite if the sulfides are indeed 
functioning as "false transmitters" as we hypothesized in our original proposal. 
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Thus, we feel we are well on our way to obtaining answers for key questions 
regarding the biochemical mechanisms behind the activities of our compounds. We 
anticipate that the data we obtain with vesicle ghosts during the coming year will 
continue to be of great value in this regard. Furthermore, we have now set up for 
adrenal cell culture in our laboratory using a borrowed laminar flow hood, and 
after a number of practice protocols and some training from colleagues at Emory, we 
have successfully cultured adrenal cells in our laboratory. Thus, we can proceed 
actively with this aspect of our program during the comimg year. 
Enzymological Studies. The complete description of the enzymology of 
our selenides, documenting their remarkable ability to deplete ascorbate via 
product recycling, was published last month in Biochemistry (see list of 
publications). 
We have now completed the full mechanistic analysis of turnover and 
suicide inhibition with our novel class of N-dealkylation DBM substrates; a major 
paper on these has been accepted for publication in the Journal of the American  
Chemical Society and is now in press. To summarize briefly, we discovered a new 
class of DBM substrates containing benzylic nitrogen atoms on which DBM exhibits a 
heretofore unknown catalytic activity -- oxygenative N -dealkylation by the enzyme 
to produce aniline and an aminoaldehyde. We extensively studied the mechanism of 
this N-dealkylating activity and firmly established that these compounds are also 
potent mechanism-based enzyme inactivators. It is clear from our mechanistic work 
that the enzymatic reaction is initiated by a single electron oxidation of the 
substrate to generate a nitrogen cation radical. After this initial step, the 
activated substrate either loses an alpha hydrogen via base-catalyzed abstraction 
to generate a carbon--centered radical which is ultimately hydrolytically cleaved to 
produce the product pair of aniline and 2-aminoacetaldehyde, or by rearrangement of 
the radical cation, causes irreversible inactivation of the enzyme via covalent 
attachment to the active site. An aspect of the N- dealkylation activity for DBM 
which is quite striking to us is that this is a direct model for the 
peptidylglycine amidating monooxygenase (PAM) enzyme which is responsible for 
generating the C-terminal amide present in so many peptide hormones of neurological 
importance. Enzymology on PAM has just started to attract a high degree of 
interest in the literature, and it isstriking that PAM is a copper and ascorbate 
requiring monooxygenase quite analogous to DBM. During the coming year we plan to 
carry out further ecoping of the relationship between our N-dealkylase activity of 
DBM and PAM, and the implications of this relationship to neurochemical processing 
and drug design. 
In January, we published (in Iliochemical Journal; see publication listing) 
our first report on the novel class of DBM substrates and inhibitors containing 
nitrogen heterocycles such as imidazole, imidazoline, and pyrazole in place of the 
amino moiety at the side chain terminus. This work has opened up a new direction 
leading to both novel substrates undergoing dealkylation, and novel potent 
competitive inhibitors. Thus, as we report, compounds such as p-hydroxy 
benzylimidazole (PHBI) are active substrates, undergoing oxygenolytic cleavage to 
4-hydroxybenzaldehyde and imidazole. In contrast, when the terminal amino group is 
replaced with pyrazole, a functionality which is uncharged at the pH of the 
enzymatic reaction, the analog possesses potent DBM competitive inhibitory 
activity. Evidence in hand is suggestive that the pyrazole moiety is interacting 
with the copper at the active site of DBM. We are now extending these findings and 
are synthesizing 2'-substituted imidazole cognates as well as analogs with altered 
side chain lengths and bis-imidazole compounds. We have carried out testing in SHR 
with the parent imidazole and pyrazole compounds but did not observe marked 
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antihypertensive activity. We will thus be very interested in obtaining bioassay 
results on these other heterocyclic analogs. 
A number of other things have been accomplished in the enzymological 
aspects of our program. For example, we have synthesized quite a number of analogs 
of our prototypic olefin inhibitor, PAME, and kinetic characterization of these is 
in progress. Non-aromatic DBM substrates have been prepared and we have 
accumulated kinetic data on these as both substrates and inhibitors. Deuteriun 
isotope effect measurements are being carried out with N-dealkylation substrates. 
Finally, we have now repeatedly used our new isolation method for DBM; using the 
purified chromaffin granules which we must prepare anyway for our uptake 
experiments, our short, fast preparative method employing FPLC techniques yield 
enzyme of 60-85 Units per mg, from much less starting material. 
Bioassay of Antihypertensive Activity. 	Both chronic and acute dosing 
protocols are now being used on a continuuing basis, and we have become quite 
expert in the surgical techniques for cannulation and direct by measurement. We 
have expanded our administration routes to now include i.p., i.v., subcutaneous, 
oral, and osmotic pump routes. Using direct measurements in cannulated SHR, we 
have in hand definitive, statistically significant antihypertensive activities for 
all four of our prototype sulfides (PAES and its HO, Me, and HOMe analogs), and a 
paper on this has been submitted to J. Cardiovas. Pharmacol. 	Striking activity 
in both acute and chronic dosing over a two week period has been obtained with our 
prototypic selenium compound, PAESe. In adjunctal experiments, whole hearts were 
removed at the end of the dosing period, and using HPLC with electrochemical 
detection, are able to demonstrate a marked change in sympathetic nerve-ending 
catecholamines in the drug-treated animals. We have found a >50% reduction in 
norepinephrine and a >70% reduction in epinephrine from hearts of animals treated 
with PAESe which correlates with the effects on blood pressure and heart rate 
already noted. In the case of PAME, similar effects have been observed. During 
the coming year we plan to continue these bioassays with our compounds using all of 
these protocols including implanted osmotic pumps to continuously deliver compound 
doses in SHR. 
Finally, in a novel approach we did not anticipate in our original 
proposal, we have successfully carried out enantiomeric resolutions for both MePAES 
and MePAESe. Preparative scale resolutions have been completed and we have 
completed X-ray struture determinations of the absolute configurations of the 
enantiomers. This is highly exciting to us, since we anticipate markedly different 
uptake interactions for the enantiomers of these compounds, but essentially no 
enzymological differences. Thus, having available these enantiomers in quantity 
sufficient for bioassay presents a telling probe of the biochemical mechanisms 
operative for our compounds. We will begin testing the individual enantiomers of 
PAESe within the next two months, and will then proceed to the sulfides. In the 
future, this approach can be extended to the other classes of compounds (olefins, 
N-compounds) as well. 
Page 9 
